Regulating Psilocybin as Food, Not Drugs
Summary
Psilocybin is considered one of the safest psychoactive substances, safer than alcohol and tobacco, yet it is classified as a Schedule I controlled substance. The essay argues for its regulation under food law instead of drug law, suggesting a framework similar to dietary supplements. It highlights the limitations of the pharmaceutical model for psilocybin and proposes a regulatory structure that includes age restrictions and dosage caps, aiming to balance public health and individual autonomy.
Study at a glance
| Key finding | Psilocybin should be regulated under food law rather than drug law, as it ranks among the safest psychoactive compounds. |
|---|
Abstract
Psilocybin is currently classified as a Schedule I controlled substance under the Controlled Substances Act-the federal designation reserved for substances deemed to have no accepted medical use and a high potential for abuse. Yet by comparative-harm metrics, psilocybin ranks among the safest psychoactive compounds in widespread use, far safer than alcohol and tobacco, both of which are statutorily exempted from the CSA and regulated as adult-use consumer commodities. This essay argues that psilocybin should likewise be regulated principally under food law-specifically the dietary-supplement framework established by the Dietary Supplement Health and Education Act of 1994-rather than under drug law. It examines the structural limits of the pharmaceutical model for a substance whose recognized benefits (well-being, creative insight, spiritual experience) do not map onto FDA disease categories; explains how the "drug exclusion clause" in 21 U.S.C. § 321(ff)(3)(B) paradoxically locks substances out of the supplement pathway precisely as their medical evidence base grows; and surveys existing precedents-U.S. CBD regulation, Dutch psilocybin truffles under the Warenwet, and Oregon's state-level treatment of psilocybin-producing fungi as a "crop"-for a workable food-law approach. The essay proposes a concrete regulatory architecture combining age restrictions, dosage caps, mandatory warning labels, current good manufacturing practices, and adverse-event reporting, and argues that food regulation offers a middle path between prohibition and medicalization that better serves public health, individual autonomy, and regulatory coherence.